Laura Hameed, Chief Executive Officer, and Dominique Pichard, MD, MS, Chief Scientific and Medical Officer of the International Rett Syndrome Foundation (IRSF), discuss the changing treatment landscape for Rett syndrome and the organization’s commitment to supporting...
Neurology/Nervous System Diseases
Rare neurological disorders are diseases of the brain, spine, and autonomic nervous system. This section provides overviews of several of those conditions, as well news, clinical trial updates, and expert opinions form leading neurologists.
FDA Approves Lembaz (Adrabetadex) for Niemann Pick Type C
The US Food and Drug Administration (FDA) has approved Lembaz (adrabetadex) for the treatment of infantile-Niemann Pick disease type C (NPC).
FDA Approves Klygefa (Gefurulimab) for AChR Antibody Positive Generalized Myasthenia Gravis
The US Food and Drug Administration (FDA) has approved Klygefa (gefurulimab) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive.
Sanofi’s Orphan Drug Supply Update | The CheckRare Brief Special Edition
On this special edition of the CheckRare Brief, we talk with Alaa Hamed, Sanofi’s Global Head of Medical Affairs for Rare Diseases, and Maite Durrenbach, Head of Specialty Care Manufacturing and Supply at Sanofi, about the company’s current supply chain problems for some of their biological therapies.
More
UCB Study Highlights the Burden of Ocular Myasthenia Gravis
Biopharmaceutical company UCB recently shared findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG). The findings were...
Highlights from The Liver Meeting 2026 | The CheckRare Brief
In this episode, we discuss highlights from The Liver Meeting, Ultragenyx program cuts, and ANI Pharmaceuticals’ offer to buy Egetis Therapeutics. Ultragenyx Ends Angelman Syndrome and...
Myasthenia Gravis
Myasthenia gravis (MG) is a chronic autoimmune disease that disrupts communication between nerves and muscles, causing fluctuating weakness that often worsens with activity. It can affect the...
Garetosmab Demonstrates Sustained Efficacy in Adults With Fibrodysplasia Ossificans Progressiva (FOP)
Richard Keen, MD, PhD, Director of the Metabolic Bone Disease Centre at the Royal National Orthopaedic Hospital in London and global principal investigator of the OPTIMA trial, discusses positive...
A Family’s Journey with Prader-Willi Syndrome
Maria Picone, co-founder and CEO of the TREND Community, and mother of a 14-year-old with Prader-Willi syndrome (PWS), discusses her family’s journey with PWS, including why more research and better...
3D Printed Treatment Options | The CheckRare Brief
In this episode, we discuss a new formulation of treatment for HAE, the FDA approval of Voceryq for recurrent respiratory papillomatosis, and 3D printed treatment options. New...
Generalized Myasthenia Gravis: AANEM 2026 Highlights
The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) held its 2026 annual meeting September 29–October 1 in Orlando. CheckRare focused its meeting coverage on generalized...
Miv-cel Shows Durable Results in Stiff Person Syndrome and Myasthenia Gravis
Naji Gehchan, MD, MBA, Chief Medical and Development Officer at Kyverna Therapeutics, discusses one-year data showing sustained benefits of KYV-101 (mivocabtagene autoleucel ; Miv-cel) in stiff...
Z-Basivarsen Shows Functional Improvements in One-Year Data for Myotonic Dystrophy Type 1
Laurie Gutmann, MD, professor of neurology at Indiana University, discusses data showing functional improvements with zeleciment basivarsen (z-basivarsen; DYNE-101) in patients with myotonic...
Ultragenyx Gets $203M in Second Priority Review Voucher This Month | The CheckRare Brief
On this episode, we discuss the FDA approval of Enspryng for TED, the new FDA Rare Disease Framework Initiative, Ultrangenyx’s second sold PRV this month, and using AI to reduce diagnostic delays....
Efficacy of Vosoritide to Treat Hypochondroplasia
Andrew Dauber, MD, MMsc, Chief of Endocrinology at Children’s National, discusses the efficacy of vosoritide to treat persons with hypochondroplasia. Hypochondroplasia is a rare...
New Stem Cell Method Could Advance Research Into Spinal Muscular Atrophy
Kyle Loh, PhD, Associate Professor at Stanford Medicine, discusses research that could help scientists better understand spinal muscular atrophy (SMA) by generating new motor neurons from human...
Ultragenyx Sells PRV for $210M | The CheckRare Brief Ep 11
In this episode, we discuss Ultragenyx’s Priority Review Voucher that sold for $210 million, the efficacy of newborn screening on MLD, and ethical considerations needed to design and conduct...
Plasma Proteomics May Predict Disease Manifestations in ALS
Michael Benatar, MD, PhD, Department of Neurology and ALS Center, University of Miami Miller School of Medicine, discusses the use of plasma proteomics in predicting clinical manifestations of...
Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval | The CheckRare Brief Ep 10
On September 28th, the FDA approved Emcitate, or tiratricol, from Egetis Therapeutics. It's the first-ever treatment for MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. ...
FDA CDER’s Accelerating Rare Disease Cures Program
Paz Vellanki, MD, PhD, Vice President of Clinical Development at Precision for Medicine, discusses the FDA CDER’s Accelerating Rare Disease Cures (ARC) Program. The ARC Program was launched...
Rett Syndrome Awareness Month
October is Rett Syndrome Awareness Month. Rett syndrome is a neurodevelopmental condition that primarily affects girls. People with the disease appear to have normal psychomotor development during...
FDA Approves First Treatment for MCT8 Deficiency
The US Food and Drug Administration (FDA) has approved Emcitate (tiratricol) for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency. MCT8...
FDA Approves Atebrioz (zilurgisertib) for Treatment of Fibrodysplasia Ossificans Progressiva
The US Food and Drug Administration (FDA) has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in patients ages 12 years and older with...
New Rare Disease Center of Excellence and FDA Advances in Rare Disease | The CheckRare Brief Ep 9
This week on The CheckRare Brief, we are joined by Eugene Lee, CMI Media Group’s Group President, Specialty Communications, for an industry perspective on some of the biggest developments in rare...
Recent Videos
Three-Year Study Finds Burosumab Improves Symptoms in Adults With X-Linked Hypophosphatemia
Trutakna Meets All Prespecified Endpoints in Phase 3 ORIGIN 3 Trial in IgA Nephropathy












International Rett Syndrome Foundation Works to Advance Research and Support Families
CheckRare 3 hours ago